---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060164"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:38:31.451224+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Q1 net loss $5.1M; FDA sets ADCOM for NurOwn ALS BLA

## Summary
- Cash and equivalents $2.2M at March 31, 2023, down from $3.0M at Dec 31, 2022.
- Net loss of $5.1M ($0.14 per share) vs. $5.4M ($0.15) in Q1 2022.
- FDA to hold Advisory Committee meeting to review NurOwn BLA for ALS; PDUFA date to be set.
- Appointed Dr. Kirk Taylor as EVP and Chief Medical Officer in April 2023.
- R&D expenses $2.9M (up from $2.6M); G&A expenses $2.2M (down from $2.9M) year-over-year.

## SEC filing metadata
- accession: 0001104659-23-060164
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923060164/0001104659-23-060164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923060164/tm2315779d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060164
- JSON: https://secwatch.observer/filing/0001104659-23-060164.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060164.txt

## Key facts
- Earnings Releases
  BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended March 31, 2023 results: net income Net loss ... was approximately $5.1 million, EPS Net loss per share ... was $0.14.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss ... was approximately $5.1 million
  - EPS: Net loss per share ... was $0.14
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2023 was approximately $5.1 million, as compared to a net loss of approximately $5.4 million for the three months ended March 31, 2022. Net loss per share for the three months ended March 31, 2023 and 2022 was $0.14 and $0.15, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923060164/0001104659-23-060164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.